New Strains. No Problem.

Californian L452R mutation.

As new strains of SARS-CoV-2 are identified across the globe, we will supply an update related to the coverage of BioGX COVID-19 assays.

On January 18, 2021, BioGX performed in silico analysis of the primer and probes used for SARS-CoV-2 diagnostics using the N1- and N2-gene regions.  A total of 793 SARS-CoV-2 genome sequences possessing the S-gene L452R mutation, (California) available in the GISAID database were analyzed for the presence of additional mutations within the N1- and N2-gene regions targeted by BioGX SARS-CoV-2 tests. 

N1-gene region

22 of the 793 SARS-CoV-2 sequences with the L452R mutation were analyzed and found to contain a single base pair mismatch.  None of the 22 SARS-CoV-2 sequences contained the mismatch in an area that may affect amplification efficiency. 

N2-gene region

29 of the 793 SARS-CoV-2 sequences analyzed have a single nucleotide mismatch in the N2 region. None of the single base pair mismatches are located in areas that would be predicted to negatively affect amplification or reporting of the BioGX assays.

BioGX utilizes primers and probes for detection of SARS-CoV-2, targeting the viral nucleocapsid gene (N gene region), human RNaseP gene as an endogenous control, and a non-naturally occurring internal amplification control (IAC).  The SARS-CoV-2 N1/N2, and RNase P primer/probe sets are based upon those designed and recommended by the US Centers for Disease Control and Prevention. The following four BioGX SARS-CoV-2 testing products utilize the US Centers for Disease Control and Prevention primer/probe set designs for N-gene region(s):

 

  1. BioGX Xfree™ COVID-19 Direct RT-PCR
  2. BD BioGX SARS-CoV-2 Reagents for BD MAX™ System 
  3. BioGX SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex 
  4. BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX™

Learn More about the UK, B.1.1.7 and South African, 501Y.V2 strains

Fully-Automated Workflow for COVID-19 & Winter Virus Testing

The BioGX multiplex COVID-19, Flu A, Flu B and RSV test is intended for the qualitative detection of RNA specific to SARS-CoV-2,  Influenza A, Influenza B, and Respiratory Syncytial Virus A/B that may be present in Pharyngeal and Nasopharyngeal swab collections in transport media and saline, obtained from individuals at risk of respiratory viral infections.

Entry with Post Format “Video”

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.

Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus.

 

Read more